Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T16688 Target Info
Target Name Diacylglycerol acyltransferase 1 (DGAT1)
Synonyms Retinol O-fatty-acyltransferase; Diglyceride acyltransferase; Diacylglycerol O-acyltransferase 1; DGAT; Acyl-CoA retinol O-fatty-acyltransferase; ARAT; AGRP1; ACAT-related gene product 1
Target Type Successful Target
Gene Name DGAT1
Biochemical Class Acyltransferase
UniProt ID
DGAT1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2014081996
Title Novel Compounds As Diacylglycerol Acyltransferase Inhibitors.
Abstract This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1 ), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGA T-1 activity may have therapeutic benefit.
Applicant(s) Glaxosmithkline Llc
Representative Drug(s) D0H9RP Drug Info N.A. Click to Show More [1]
2 D0U0MZ Drug Info N.A. [1]
Patent ID WO2014081995
Title Novel Compounds As Diacylglycerol Acyltransferase Inhibitors.
Abstract This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit.
Applicant(s) Glaxosmithkline Llc
Representative Drug(s) D0H9RP Drug Info N.A. Click to Show More [1]
2 D0U0MZ Drug Info N.A. [1]
Patent ID WO2014081994
Title Novel Compounds As Diacylglycerol Acyltransferase Inhibitors.
Abstract This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1 ), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit.
Applicant(s) Glaxosmithkline Llc
Representative Drug(s) D0H9RP Drug Info N.A. Click to Show More [1]
2 D0U0MZ Drug Info N.A. [1]
Patent ID WO2012162129
Title Novel Compounds As Diacylglycerol Acyltransferase Inhibitors.
Abstract This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
Applicant(s) Glaxosmithkline Intellectual Property (No.2) Limited
Representative Drug(s) D0H9RP Drug Info N.A. Click to Show More [1]
2 D0U0MZ Drug Info N.A. [1]
Patent ID WO2009126624
Title Triazolo Compounds Useful As Dgat1 Inhibitors.
Abstract Disclosed are triazolopyridine compounds of Formula (I), including pharmaceutically acceptable salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D02CTG Drug Info N.A. Click to Show More [1]
2 D02NRD Drug Info N.A. [1]
3 D08UCB Drug Info N.A. [1]
4 D0F1CE Drug Info N.A. [1]
5 D0MX3Y Drug Info N.A. [1]
Patent ID WO2013130370
Title Compounds As Dgat-1 Inhibitors.
Abstract Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0QT3C Drug Info N.A. [1]
Patent ID WO2013096093
Title Compounds As Dgat-1 Inhibitors.
Abstract Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D01DHT Drug Info N.A. [1]
Patent ID WO2012122075
Title Lactam Derivatives As Dgat-1 Inhibitors.
Abstract Described herein are compounds of formula I The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D04QGW Drug Info N.A. [1]
Patent ID WO2012112364
Title Lactam Derivatives As Dgat-1 Inhibitors.
Abstract Described herein are compounds of formula I The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D0A8SI Drug Info N.A. [1]
Patent ID WO2012024179
Title Substituted Amide Derivatives As Dgat-1 Inhibitors.
Abstract Described herein are compounds of formula I. The compounds of formula I act as DGAT-1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D05REP Drug Info N.A. [1]
Patent ID WO2011121350
Title 4 -Amino -7,8- Dihydropyrimido [5, 4 - F] [1, 4] Oxazepin- 5 ( 6H) - One Based Dgat1 Inhibitors.
Abstract DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.
Applicant(s) Astrazeneca Ab
Representative Drug(s) D0F6VD Drug Info N.A. [1]
Patent ID WO2011071840
Title Inhibitors of Diacylglycerol Acyltransferase.
Abstract This invention provides compounds of formula (I) : or a pharmaceutically acceptable salt thereof as inhibitors of diacylglycerol acyltransferase 1 (DGAT-1); as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.
Applicant(s) Eli Lilly and Company
Representative Drug(s) D04EFQ Drug Info N.A. [1]
Patent ID WO2011031628
Title Inhibitors of Diacylglycerol Acyltransferase.
Abstract The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (DGAT) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below:.
Applicant(s) Schering Corp
Representative Drug(s) D0OT8R Drug Info N.A. [1]
Patent ID WO2010146395
Title Pyrazine Carboxamides As Inhibitors of Dgat1.
Abstract DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X1 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or - CONHSO2 Me or ONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is ONRbRc the Rb and Rc groups may be optionally substituted by carboxy.
Applicant(s) Astrazeneca Ab
Representative Drug(s) D0H2WY Drug Info N.A. [1]
Patent ID WO2010070343
Title 1,3,4-Oxadiazole Derivatives and Their Uses To Treat Diabetes.
Abstract DGAT-1 inhibitor compounds of formula (I) and pharmaceutically-acceptable salts thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity (I) wherein n is 0, 1, 2 or 3, R is independently selected from fluoro, chloro, bromo, trifluoromethyl, methoxy, difluoromethoxy and trifluoromethoxy and Z is carboxy or a mimic or bioisostere thereof, hydroxyl, hydroxymethyl, or ONRbRc wherein Rb and Rc are independently selected from hydrogen and (1-4C)alkyl, which (1-4C)alkyl group may be optionally substituted by carboxy or a mimic or bioisostere thereof.
Applicant(s) Astrazeneca Ab
Japan Patent Office (JPO)
Patent ID JP8182496
Title Substance fo-2942 and its production.
Representative Drug(s) D0N0WE Drug Info N.A. [1]
References  Top
REF 1 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.